Breaking News
0
Ad-Free Version. Upgrade your Investing.com experience. Save up to 40% More details
Close

Grifols SA Pref (0RDV)

Create Alert
New!
Create Alert
Website
  • As an alert notification
  • To use this feature, make sure you are signed-in to your account
Mobile App
  • To use this feature, make sure you are signed-in to your account
  • Make sure you are signed-in with the same user profile

Condition

Frequency

Once
%

Frequency

Frequency

Delivery Method

Status

Add to/Remove from a Portfolio Add to Portfolio
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
15.38 -0.07    -0.42%
18/06 - Closed. Currency in EUR ( Disclaimer )
Type:  Equity
Market:  United Kingdom
ISIN:  ES0171996095 
SEDOL:  BYZQYD1
  • Volume: 9,107
  • Bid/Ask: 0.00 / 0.00
  • Day's Range: 15.38 - 15.38
Grifols Pref 15.38 -0.07 -0.42%
IndustryBiotechnology & Drugs
SectorHealthcare
Employees

23668

Equity Type

Preferred

Grifols SA is a Spain-based global specialty pharmaceutical company developing, manufacturing and distributing a broad range of biological medicines based on plasma derived proteins. It organizes its business into five divisions: Bioscience, Diagnostic, Hospital, Bio Supplies and Others. Bioscience includes manufacturing activities of plasma derivatives for therapeutic use and the sale and distribution of end products. Diagnostic focuses on researching, developing, manufacturing and marketing in vitro diagnostics products, such as analytical instruments, reagents and software, among others, for laboratories. Hospital offers technology and services for hospitals, clinics and specialized centers for the manufacture of medicines, as well as physiological saline solution, enteral nutritional fluids and medical devices for interventional therapy. Bio Supplies provides, mostly, biological products for non-therapeutic use. Others provides manufacturing services to third party companies.

Contact Information

Phone +34-935-710000
Fax 935-710267

Top Executives

Name Age Since Title
Victor Grifols Roura - 2017 Non-Executive Chairman of the Board
Ramon Riera Roca - 2018 Director
Tomas Daga Gelabert - 2016 Vice Secretary, Director
Thomas Glanzmann 62 2017 Non-Executive Vice Chairman of the Board
Alfredo Arroyo Guerra - 2014 Chief Financial Officer
Nuria Pascual Lapena - 2019 VP Corporate Treasury & Investor Relations
Vicente Blanquer Torre - 2014 Vice President - Quality & Regulatory affairs
Raimon Grifols Roura - 2017 Co-Chief Executive Officer, Executive Director
Nuria Martin Barnes - 2015 Non-Member Secretary of the Board of Directors
Mateo Borras Humbert - 2014 Chief Human Resource Officer
Alberto Grifols Roura - 2019 President - Commercial Operations Management
Miguel Pascual Montblanch - 2019 President, Commercial Operations Management
Steven F. Mayer 59 2016 Independent Director
David Bell - 2017 General Counsel and Chief Innovation Officer
Joel Abelson - 2018 President, Bioscience Commercial Division
Belen Villalonga Morenes - 2013 Independent Director
Marla Elizabeth Salmon - 2014 Independent Director
Lafmin Morgan 55 2018 Chief Commercial Officer
Carina Szpilka Lazaro 52 2015 Independent Director
Inigo Sanchez Asiain Mardones - 2017 Lead Independent Director
Victor Grifols Deu - 2017 Co-Chief Executive Officer, Executive Director
Enriqueta Felip Font - 2019 Independent Director
Matt Murawski - 2019 VP Innovation Operations & Analytics
Maria Teresa Rione - - Vice President - Corporate Communications
Javier Sueiras Gil - 2018 Chief IT Officer
Luis Twose Garcon - 2018 Managing Director - Laboratorios Grifols
Daniel Fleta Coit - 2019 Chief Industrial Officer
Albert Grifols Coma-Cros - - President, Grifols Worldwide Operations
James Costos 57 2020 Independent Director
Chris Healey - 2020 President, Na Corporate Affairs
Comment Guidelines

We encourage you to use comments to engage with users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind: 

  • Enrich the conversation
  • Stay focused and on track. Only post material that’s relevant to the topic being discussed.
  • Be respectful. Even negative opinions can be framed positively and diplomatically.
  •  Use standard writing style. Include punctuation and upper and lower cases.
  • NOTE: Spam and/or promotional messages and links within a comment will be removed
  • Avoid profanity, slander or personal attacks directed at an author or another user.
  • Don’t Monopolize the Conversation. We appreciate passion and conviction, but we also believe strongly in giving everyone a chance to air their thoughts. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

GRLSbn Comments

Write your thoughts about Grifols SA Pref
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All derived (stocks, indexes, futures), cryptocurrencies, and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn't bear any responsibility for any trading losses you might incur as a result of using this data.
Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.
Continue with Google
or
Sign up with Email